Generex Biotechnology Announces Merger with Public Vehicle for Public Trading of NuGenerex Immuno-Oncology

Ads

You May Also Like

Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer

PRESS RELEASE Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer (Oxford, UK and Conshohocken, ...

VBL Therapeutics Awarded $2.5 Million Grant by the Israel Innovation Authority

TEL AVIV, Israel, June 08, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT) today announced ...

Surface Oncology to Present at 2018 UBS Global Healthcare Conference

CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology ...